|
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
BCAR4 expression strongly sensitised ZR-75-1 and MCF7 breast cancer cells to the combination of lapatinib and antioestrogens.
|
22892392 |
2012 |
|
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
The clinical significance of combining BCAR4 and ERBB2 mRNA status was underscored by the finding that the group of patients having BCAR4-positive/ERBB2-low-expressing cancers had a shorter PFS on tamoxifen treatment than the BCAR4-negative group.
|
22892392 |
2012 |
|
Oestrogen receptor positive breast cancer
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
This study shows that BCAR4 expression identifies a subgroup of ER-positive breast cancer patients without overexpression of ERBB2 who have a poor outcome and might benefit from combined ERBB2-targeted and antioestrogen therapy.
|
22892392 |
2012 |
|
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
BCAR4 expression correlates with advanced breast cancers, and therapeutic delivery of locked nucleic acids (LNAs) targeting BCAR4 strongly suppresses breast cancer metastasis in mouse models.
|
25416949 |
2014 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
BCAR4 expression correlates with advanced breast cancers, and therapeutic delivery of locked nucleic acids (LNAs) targeting BCAR4 strongly suppresses breast cancer metastasis in mouse models.
|
25416949 |
2014 |
|
Neoplasm Metastasis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
BCAR4 expression correlates with advanced breast cancers, and therapeutic delivery of locked nucleic acids (LNAs) targeting BCAR4 strongly suppresses breast cancer metastasis in mouse models.
|
25416949 |
2014 |
|
Malignant neoplasm of breast
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
BCAR4 mRNA expression was evaluated by (q)RT-PCR in a panel of human normal tissues, primary breast cancers and cell lines.
|
26317614 |
2015 |
|
Malignant neoplasm of breast
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
LncRNA BCAR4 wires up signaling transduction in breast cancer.
|
26016563 |
2015 |
|
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Here, we show high level of expression and function of BCAR4 in human breast cancer.
|
26317614 |
2015 |
|
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
LncRNA BCAR4 wires up signaling transduction in breast cancer.
|
26016563 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Lapatinib, a clinically approved EGFR/ERBB2 inhibitor, counteracts BCAR4-driven tumor cell growth, a clinical relevant observation.
|
26317614 |
2015 |
|
Testicular Germ Cell Tumor
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Identification of four new susceptibility loci for testicular germ cell tumour.
|
26503584 |
2015 |
|
Breast cancer, lobular
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Relative high BCAR4 mRNA expression was identified in IPH-926, a cell line derived from an endocrine-resistant lobular breast cancer.
|
26317614 |
2015 |
|
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
Long noncoding RNA (lncRNA) is a new type of RNA molecule, which plays pivotal roles in many tumors. lncRNA BCAR4 has been identified as an oncogenetic lncRNA involved in the progression of breast cancer.
|
27460090 |
2016 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Long noncoding RNA (lncRNA) is a new type of RNA molecule, which plays pivotal roles in many tumors. lncRNA BCAR4 has been identified as an oncogenetic lncRNA involved in the progression of breast cancer.
|
27460090 |
2016 |
|
Neoplasm Metastasis
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
The BCAR4 levels were significantly correlated with clinical stage and distant metastasis.
|
27874956 |
2016 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Increased expression of BCAR4 was significantly correlated with large tumor size, advanced Enneking stage, lung metastasis, and poor prognosis.
|
27460090 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The results of the present study identified a crucial tumor promotive role of BCAR4 in the progression of osteosarcoma, and suggested that BCAR4 may be a potential therapeutic agent for the treatment of osteosarcoma.
|
27874956 |
2016 |
|
Osteosarcoma
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
We found that BCAR4 expression was higher in osteosarcoma tissues and cell lines than that in normal controls.
|
27874956 |
2016 |
|
Osteosarcoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
Consistently, knockdown of BCAR4 inhibits osteosarcoma tumorigenesis and lung metastasis in vivo.
|
27460090 |
2016 |
|
Osteosarcoma of bone
|
0.050 |
Biomarker
|
disease |
BEFREE |
Consistently, knockdown of BCAR4 inhibits osteosarcoma tumorigenesis and lung metastasis in vivo.
|
27460090 |
2016 |
|
Osteosarcoma of bone
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
We found that BCAR4 expression was higher in osteosarcoma tissues and cell lines than that in normal controls.
|
27874956 |
2016 |
|
Childhood Osteosarcoma
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
We found that BCAR4 expression was higher in osteosarcoma tissues and cell lines than that in normal controls.
|
27874956 |
2016 |
|
Childhood Osteosarcoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
Consistently, knockdown of BCAR4 inhibits osteosarcoma tumorigenesis and lung metastasis in vivo.
|
27460090 |
2016 |
|
Tumor Cell Invasion
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
Up-regulation of long non-coding RNA BCAR4 predicts a poor prognosis in patients with osteosarcoma, and promotes cell invasion and metastasis.
|
27874956 |
2016 |